作者
Sylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, Larissa A Korde, Elad Sharon, Laleh Amiri-Kordestani, Harry Bear, Heather L McArthur, Elizabeth Frank, Jane Perlmutter, David B Page, Benjamin Vincent, Jennifer F Hayes, James L Gulley, Jennifer K Litton, Gabriel N Hortobagyi, Stephen Chia, Ian Krop, Julia White, Joseph Sparano, Mary L Disis, Elizabeth A Mittendorf
发表日期
2019/8/1
来源
JAMA oncology
卷号
5
期号
8
页码范围
1205-1214
出版商
American Medical Association
简介
Importance
There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease.
Observations
After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy …
学术搜索中的文章
S Adams, ME Gatti-Mays, K Kalinsky, LA Korde… - JAMA oncology, 2019